At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
AZD7648 +1 moredrug
Likely dose
PLD 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
In Brief
A Phase 2 clinical trial evaluating AZD7648 and PLD for Advanced Malignancies. Completed, enrolled 30 participants across 5 sites in 2 countries.
Detailed Summary
This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies
CountriesUnited Kingdom, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartOct 2019
Primary CompletionDec 2022
TodayJul 2026
First PostedApr 9, 2019
Enrollment StartOct 9, 2019
Primary CompletionDec 7, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.2 years ago
Interventions
AZD7648drug
Core: AZD7648 will be administered orally
PLDdrug
The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles